Stratec SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. More Details
Solid track record with adequate balance sheet and pays a dividend.
Share Price & News
How has Stratec's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SBS is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: SBS's weekly volatility (5%) has been stable over the past year.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: SBS exceeded the German Medical Equipment industry which returned 24.2% over the past year.
Return vs Market: SBS matched the German Market which returned 39.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Stratec's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StHere's Why Shareholders Will Not Be Complaining About Stratec SE's (ETR:SBS) CEO Pay Packet
5 days ago | Simply Wall StStratec SE (ETR:SBS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
1 month ago | Simply Wall StStratec (ETR:SBS) Shareholders Have Enjoyed An Impressive 129% Share Price Gain
Is Stratec undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SBS (€110.4) is trading above our estimate of fair value (€96.06)
Significantly Below Fair Value: SBS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SBS is poor value based on its PE Ratio (37.6x) compared to the German Medical Equipment industry average (35.1x).
PE vs Market: SBS is poor value based on its PE Ratio (37.6x) compared to the German market (25.9x).
Price to Earnings Growth Ratio
PEG Ratio: SBS is poor value based on its PEG Ratio (3.1x)
Price to Book Ratio
PB vs Industry: SBS is good value based on its PB Ratio (7.3x) compared to the DE Medical Equipment industry average (7.6x).
How is Stratec forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SBS's forecast earnings growth (12.1% per year) is above the savings rate (0.01%).
Earnings vs Market: SBS's earnings (12.1% per year) are forecast to grow slower than the German market (16.2% per year).
High Growth Earnings: SBS's earnings are forecast to grow, but not significantly.
Revenue vs Market: SBS's revenue (7.4% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: SBS's revenue (7.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SBS's Return on Equity is forecast to be low in 3 years time (19%).
How has Stratec performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SBS has high quality earnings.
Growing Profit Margin: SBS's current net profit margins (13.4%) are higher than last year (7.8%).
Past Earnings Growth Analysis
Earnings Trend: SBS's earnings have grown by 4% per year over the past 5 years.
Accelerating Growth: SBS's earnings growth over the past year (103.3%) exceeds its 5-year average (4% per year).
Earnings vs Industry: SBS earnings growth over the past year (103.3%) exceeded the Medical Equipment industry 58.9%.
Return on Equity
High ROE: SBS's Return on Equity (19.4%) is considered low.
How is Stratec's financial position?
Financial Position Analysis
Short Term Liabilities: SBS's short term assets (€181.0M) exceed its short term liabilities (€46.7M).
Long Term Liabilities: SBS's short term assets (€181.0M) exceed its long term liabilities (€126.8M).
Debt to Equity History and Analysis
Debt Level: SBS's debt to equity ratio (51.3%) is considered high.
Reducing Debt: SBS's debt to equity ratio has increased from 3.9% to 51.3% over the past 5 years.
Debt Coverage: SBS's debt is well covered by operating cash flow (45.5%).
Interest Coverage: SBS's interest payments on its debt are well covered by EBIT (30.8x coverage).
What is Stratec current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: SBS's dividend (0.82%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.06%).
High Dividend: SBS's dividend (0.82%) is low compared to the top 25% of dividend payers in the German market (3.26%).
Stability and Growth of Payments
Stable Dividend: SBS's dividends per share have been stable in the past 10 years.
Growing Dividend: SBS's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (30.6%), SBS's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: SBS's dividends in 3 years are forecast to be well covered by earnings (32.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Marcus Wolfinger (53 yo)
Mr. Marcus Wolfinger has been Chairman of Management Board and Chief Executive Officer at Stratec SE (formerly known as STRATEC Biomedical AG) since April 01, 2011 and its Member of the Management Board si...
CEO Compensation Analysis
Compensation vs Market: Marcus's total compensation ($USD1.49M) is about average for companies of similar size in the German market ($USD1.59M).
Compensation vs Earnings: Marcus's compensation has been consistent with company performance over the past year.
Experienced Management: SBS's management team is seasoned and experienced (10.1 years average tenure).
Experienced Board: SBS's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Stratec SE's company bio, employee growth, exchange listings and data sources
- Name: Stratec SE
- Ticker: SBS
- Exchange: XTRA
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €1.336b
- Shares outstanding: 12.10m
- Website: https://www.stratec.com
Number of Employees
- Stratec SE
- Gewerbestrasse 35-37
Stratec SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. It operates through three segments: Inst...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/15 18:42|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.